

1 **Rapid detection of SARS-CoV-2 variants of concern identifying a cluster of B.1.1.28/P.1**  
2 **variant in British Columbia, Canada**

3 Nancy Matic<sup>1,2\*</sup>, Christopher F. Lowe<sup>1,2\*</sup>, Gordon Ritchie<sup>1,2</sup>, Aleksandra Stefanovic<sup>1,2</sup>, Tanya  
4 Lawson<sup>1</sup>, Willson Jang<sup>1</sup>, Matthew Young<sup>1</sup>, Winnie Dong<sup>3</sup>, Zabrina L. Brumme<sup>3,4</sup>, Chanson J.  
5 Brumme<sup>3,5</sup>, Victor Leung<sup>1,2,5</sup>, Marc G. Romney<sup>1,2</sup>

6 <sup>1</sup> Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada

7 <sup>2</sup> Department of Pathology and Laboratory Medicine, University of British Columbia,  
8 Vancouver, Canada

9 <sup>3</sup> British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada

10 <sup>4</sup> Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

11 <sup>5</sup> Department of Medicine, University of British Columbia, Vancouver, British Columbia,  
12 Canada

13 \* These first authors contributed equally to this article.

14 Word Count: 50

15 Abstract Word Count: 1,197

16

17 **Corresponding Author:**

18 Dr. Marc G. Romney

19 St. Paul's Hospital, Providence Health Care

20 1081 Burrard St.

21 Vancouver, BC, Canada V6Z 1Y6

22 Email: [mromney@providencehealth.bc.ca](mailto:mromney@providencehealth.bc.ca)

23 Tel: 604-806-8188

24 **Abstract**

25 Using a real-time RT-PCR-based algorithm to detect SARS-CoV-2 variants of concern, we  
26 rapidly identified 77 variants (57-B.1.1.7, 7-B.1.351, and 13-B.1.1.28/P.1). This protocol enabled  
27 our laboratory to screen all SARS-CoV-2 positive samples for variants, and identified a cluster  
28 of B.1.1.28/P.1 cases, a variant not previously known to circulate in British Columbia.

29

30

## 31 **Introduction**

32 A robust surveillance system for early identification of SARS-CoV-2 variants of concern  
33 (VOC) is of critical public health importance. VOC have demonstrated *in vitro* evasion of  
34 antibody neutralization by the K417N/T, E484K, and N501Y substitutions in the spike  
35 protein(1–3), and have displayed potential for enhanced transmission due to mutations within the  
36 spike receptor binding domain(4,5). Surveillance data from the United Kingdom demonstrated a  
37 rapid increase in SARS-CoV-2 cases beginning in September 2020, subsequently attributed to  
38 the B.1.1.7 variant(6). This variant has since become the predominant strain in several European  
39 countries, and its prevalence is increasing worldwide(7). The B.1.1.7 variant demonstrated  
40 dropout of the S gene on a commercial SARS-CoV-2 real-time RT-PCR assay in the UK due to a  
41 deletion mutation within the spike protein (69/70), and subsequently proposed as a surveillance  
42 strategy by the European Centre for Disease Prevention and Control(8).

43 The B.1.1.28/P.1 variant is an emerging VOC with cases first documented in Japan and  
44 Brazil. Within months, it has become the predominant strain in certain regions of Brazil, and has  
45 now been detected across several continents, although relatively few cases have been detected in  
46 Canada and the United States to date. Re-infection in patients with pre-existing SARS-CoV-2  
47 immunity has been described, raising concerns about resurgence(9). Unlike B.1.1.7, the  
48 B.1.1.28/P.1 variant does not possess the 69/70 deletion mutation, highlighting the need for a  
49 versatile and comprehensive VOC surveillance strategy capable of detecting multiple mutations.

50 Given the potential for VOC to enhance transmission and mortality, and possibly evade  
51 natural and/or vaccine-induced immune responses, it is critical to identify VOC cases and  
52 monitor their prevalence. Though whole-genome sequencing (WGS) of random subsets of  
53 SARS-CoV-2 samples is a core surveillance strategy, this laborious and costly strategy is

54 currently limited by lack of scalability and prolonged turnaround time. We propose a rapid VOC  
55 surveillance strategy using multiple real-time RT-PCR assays designed to detect key mutations  
56 among all specimens testing positive for SARS-CoV-2 in a clinical diagnostic laboratory.

## 57 **Methods**

58 From January 25–March 1, 2021, nasopharyngeal swabs and saliva/mouth rinse samples  
59 with SARS-CoV-2 detected at any cycle threshold (Ct) value (reported as ‘positive’ or  
60 ‘indeterminate’) in our clinical virology laboratory were subsequently tested for VOC. SARS-  
61 CoV-2 detection was performed using the LightMix® ModularDx SARS-CoV (COVID19) E-  
62 gene assay (TIB Molbiol, Berlin, Germany), with use of the MagNA Pure Compact or MagNA  
63 Pure 96 and LightCycler 480, or with the cobas® SARS-CoV-2 Test (Roche Molecular  
64 Diagnostics, Laval, QC) on the cobas® 6800. VOC were detected with the VirSNiP SARS-CoV-  
65 2 Mutation Assays for Strain Surveillance (TIB Molbiol), targeting specific spike protein  
66 variations (N501Y, delHV69/70, K417N, E484K, V1176F). Samples were first screened for  
67 N501Y, and if detected, subsequent targets were re-tested to discriminate between the most  
68 prevalent VOC within our community (B.1.1.7-delHV69/70 and B.1.351-K417N) and newly  
69 emerging VOC (B.1.1.28/P.1-V1176F).

70 WGS was performed on the MinION (Oxford Nanopore Technologies) using the ARTIC  
71 nCOV-2019 sequencing protocol V.1 (J. Quick) using V3 primers or Illumina MiSeq with a  
72 modified ARTIC nCOV-2019 protocol. Accurate basecalling of MinION was performed using  
73 guppy 3.1.5, and FASTQ files analyzed on the bugseq.com platform using pangoleARN.  
74 Illumina sequence data were analyzed with the in-house bioinformatics pipeline MiCall(10).

75 This study was approved by the Providence Health Care/University of British Columbia  
76 and Simon Fraser University Research Ethics Boards (H20-01055).

## 77 **Results**

78           During the study period, 31,833 clinical samples were tested for SARS-CoV-2, with  
79 2,618 instances of SARS-CoV-2 detected at any Ct value. Of these, 2,430 (92.8%) underwent  
80 subsequent testing for the three major VOC categories (B.1.1.7; B.1.351; B.1.1.28/P.1). Note that  
81 1.6% (38/2,430) of the samples failed to amplify using the N501Y assay, of which 71% (27/38)  
82 were reported as ‘indeterminate’ for SARS-CoV-2, reflecting late Ct values and presumably low  
83 viral loads. From the remaining 2,392 samples, 77 VOC were identified (57-B.1.1.7, 7-B.1.351,  
84 and 13-B.1.1.28/P.1). Over the course of the study, VOC detection among diagnostic samples  
85 rapidly increased (Figure). Notably, identified VOC included a large cluster of the B.1.1.28/P.1  
86 variant not previously identified in British Columbia. All B.1.1.28/P.1 variants were initially  
87 suspected from the K417N assay, for which PCR products were identified at a lower melting  
88 temperature than expected. All the suspected B.1.1.28/P.1 variants were positive when re-  
89 screened using the V1176F target. The first presumptive B.1.1.28/P.1 variant identified was  
90 confirmed by WGS, detecting the following mutations in the S gene (characteristic of  
91 B.1.1.28/P.1): L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y,  
92 T1027I, and V1176F. Sequencing also confirmed B.1.1.7 and B.1.351 samples detected by our  
93 PCR-based strategy.

## 94 **Discussion**

95           Timely identification is critical to identify emerging SARS-CoV-2 VOC that may be  
96 more transmissible, pathogenic and/or evade both natural and vaccine-induced immunity. The  
97 implementation of a PCR-based algorithm to detect VOC has enabled our laboratory to rapidly  
98 detect new variants that are in the very early stages of community transmission. Critically, our  
99 protocol enabled detection of VOC within 24 hours of COVID-19 diagnosis, a marked advantage

100 over sequencing-based surveillance strategies. Over the study period, VOC positivity rate was  
101 3.2%, but detection rates increased markedly over time, as might be expected with exponential  
102 growth observed in other countries.

103 Although B.1.1.28/P.1 had not previously been reported in our region, presence of this  
104 variant was suspected upon observation of K417N PCR products with a lower melting  
105 temperature than wild-type, suggestive of a non-K417N substitution such as the K417T mutation  
106 in the B.1.1.28/P.1 variant(11). Follow-up testing of these samples using the V1176F target  
107 supported the presumptive identification of B.1.1.28/P.1, which was subsequently confirmed by  
108 WGS. By testing all positive SARS-CoV-2 samples for VOC, it enabled the rapid detection of a  
109 discrete, new B.1.1.28/P.1 cluster.

110 Although the primary modality of VOC surveillance has been through WGS, universal  
111 sequencing of SARS-CoV-2 positive specimens is limited by both laboratory and bioinformatics  
112 capacity(12). Due to the volume of VOC testing required, high complexity and cost of WGS and  
113 limited laboratory capacity, turnaround time for VOC by WGS may be on the order of days to  
114 weeks. With the onset of the COVID-19 pandemic, molecular diagnostics (i.e., PCR) have been  
115 increasingly adopted by laboratories to promptly identify SARS-CoV-2 cases, with infrastructure  
116 established for this modality of testing. A PCR-based algorithm for the molecular detection of  
117 VOC could be rapidly adopted to provide almost real-time resulting of VOC to inform infection  
118 prevention and control and public health measures(7,13,14).

119 While the most prevalent VOC worldwide harbour the N501Y spike mutation, it is not  
120 present in all variants(15). A PCR-based algorithm for identifying VOC that uses N501Y as the  
121 initial screening target, such as in this study, must acknowledge this limitation. Given the rapid  
122 emergence of new variants, ongoing surveillance is key, and any laboratory considering a PCR-

123 based algorithm would need to adapt the algorithm as VOC prevalence changes. Nevertheless,  
124 the ability to rapidly leverage existing molecular infrastructure established during the COVID-19  
125 pandemic to presumptively identify the most prevalent VOC within 24 hours would be an  
126 important tool to complement WGS performed at reference laboratories.

127 In summary, our implementation of a real-time RT-PCR-based algorithm enabled  
128 identification of the most common VOC to date (B.1.1.7, B.1.351, and B.1.1.28/P.1) within 24  
129 hours. This methodology would allow laboratories to perform VOC testing on all positive SARS-  
130 CoV-2 samples, and enhance VOC surveillance capacity to identify cases and support decision  
131 making for interrupting transmission.

### 132 **Acknowledgements**

133 We are grateful to our medical laboratory technologists who are highly committed to  
134 patient care and laboratory quality improvement. We would also like to acknowledge  
135 contributions from John Harding and Althea Hayden [Vancouver Coastal Health (VCH) Public  
136 Health], and the BCCDC Public Health Laboratory.

137 This work was supported by COVID-19 rapid response grants from GenomeBC (COV-  
138 115 to ZLB, CFL; COV-033 to CJB), an Exceptional Opportunities Fund – COVID-19 award  
139 from the Canada Foundation for Innovation (CJB, CFL), a British Columbia Ministry of Health -  
140 Providence Health Care Research Institute COVID-19 Research Priorities Grant (CJB, CFL) and  
141 Public Health Agency of Canada COVID-19 Immunology Task Force COVID-19 Hot Spots  
142 Competition Grant (ZLB, MGR). GR reports participation as a Roche Diagnostics Sequencing  
143 Advisory Panel member. ZLB holds a Scholar Award from the Michael Smith Foundation for  
144 Health Research.

145

146 **References**



- 147 1. Liu Y, Liu J, Xia H, Xianwen Z, Fontes-Garfias CR, Swanson KA, et al. Neutralizing  
148 Activity of BNT162b2-Elicited Serum — Preliminary Report. *N Engl J Med* [Internet].  
149 2021 Feb 28. <https://www.nejm.org/doi/full/10.1056/NEJMc2102017>
- 150 2. Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, et al. Neutralization of SARS-  
151 CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited  
152 sera. *Nat Med* [Internet]. 2021 Mar 1. [https://www.nature.com/articles/s41591-021-01270-](https://www.nature.com/articles/s41591-021-01270-4)  
153 4
- 154 3. Garcia-Beltran WF, Lam EC, Denis KS, Nitido AD, Garcia ZH, Hauser BM, et al.  
155 Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral  
156 immunity. *medRxiv* [Internet]. 2021 Mar 2.  
157 <https://www.medrxiv.org/content/10.1101/2021.02.14.21251704v1>
- 158 4. Nelson G, Buzko O, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Molecular  
159 dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the  
160 combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces  
161 conformational change greater than N501Y mutant alone, potentially resulting in an  
162 escape mutant. *bioRxiv* [Internet]. 2021 Mar 3.  
163 <https://www.biorxiv.org/content/10.1101/2021.01.13.426558v1>
- 164 5. Liu H, Wei P, Zhang Q, Chen Z, Aviszus K, Downing W, et al. 501Y.V2 and 501Y.V3  
165 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro. *bioRxiv* [Internet]. 2021  
166 Mar 2. <https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1>
- 167 6. Public Health England. Investigation of novel SARS-COV-2 variant: Variant of Concern  
168 202012 / 01. 2020 Dec 21 [cited 2021 Mar 3].



- 169 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_d](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf)  
170 [ata/file/959438/Technical\\_Briefing\\_VOC\\_SH\\_NJL2\\_SH2.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf)
- 171 7. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A.  
172 Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January  
173 12, 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(3):95–9.
- 174 8. European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2  
175 variant with multiple spike protein mutations observed in the United Kingdom. 2020 Dec  
176 20 [cited 2021 Mar 3]. [https://www.ecdc.europa.eu/sites/default/files/documents/SARS-](https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf)  
177 [CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf)
- 178 9. Souza WM, Amorim MR, Sesti-Costa R, Coimbra LD, Toledo-Teixeira DA, Parise PL, et  
179 al. Levels of SARS-CoV-2 lineage P.1 neutralization by antibodies elicited after natural  
180 infection and vaccination. *Pre-Prints with Lancet [Internet]*. 2021 Mar 2.  
181 [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3793486](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3793486)
- 182 10. MiCall: Processing FASTQ data from an Illumina MiSeq. [cited 2021 Mar 3].  
183 <https://github.com/cfe-lab/MiCall>
- 184 11. VirSNiP SARS-CoV-2 Spike K417N Package Insert, TIB Molbiol, Germany. 2020;
- 185 12. World Health Organization. Genomic sequencing of SARS-CoV-2: A guide to  
186 implementation for maximum impact on public health. 2021 Jan 8 [cited 2021 Mar 3].  
187 <https://www.who.int/publications/i/item/9789240018440>
- 188 13. Ontario Agency for Health Protection and Promotion (Public Health Ontario), Provincial  
189 Infectious Diseases Advisory Committee. Interim guidance for infection prevention and  
190 control of SARS-CoV-2 variants of concern for health care settings. 2021 Feb 10 [cited  
191 2021 Mar 3]. [https://www.publichealthontario.ca/-](https://www.publichealthontario.ca/)

- 192            /media/documents/ncov/voc/2021/02/pidac-interim-guidance-sars-cov-2-  
193            variants.pdf?la=en
- 194    14.    European Centre for Disease Prevention and Control. Risk Assessment: Risk related to the  
195            spread of new SARS-CoV-2 variants of concern in the EU/EEA-first update. 2021 Jan 21  
196            [cited 2021 Mar 3]. [https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-  
197            assessment-spread-new-variants-concern-eueea-first-update](https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update)
- 198    15.    Zhang W, Davis B, Chen S, Sincuir Martinez JM, Plummer JT, Vail E. Emergence of a  
199            Novel SARS-CoV-2 Variant in Southern California. JAMA [Internet]. 2021 Feb 28.  
200            <https://jamanetwork.com/journals/jama/fullarticle/2776543>  
201  
202

203 **Figure:** Detection rate of SARS-CoV-2 variants of concern by day of result for the study period  
204 of January 25 to March 1, 2021, with 7-day moving average

**B.1.1.7 (UK)****B.1.351 (South African)****B.1.1.28/P.1 (Brazilian)**